July 1 (Reuters) - AstraZeneca ( AZN ) CEO Pascal Soriot

is considering moving the company's stock market listing to the

U.S., the Times reported on Tuesday, citing multiple sources.

Soriot has privately expressed a preference to shift the

FTSE 100 company's listing on multiple occasions and has also

discussed relocating AstraZeneca's ( AZN ) domicile, the report said.

The company declined to comment on the report.

The UK pharmaceutical giant already has American

depositary receipts trading in the U.S.

Soriot could face opposition from some board members and the

British government if he pursues the move, according to the

report, adding that the government has not been informed.

London-listed shares in AstraZeneca ( AZN ) were up 2.7% at

10,400 pence at 1504 GMT.